FDA feedback supports BiomX’s plan to advance its phage-based therapy into DFI as the next clinical indication, following the Company’s previous Phase 2 study of BX211, a phage product for the ...

FBLG READ THE FULL FBLG RESEARCH REPORT Business Update Phase 1/2 Trial in Diabetic Foot Ulcers to Initiate in 1Q26 ...

GUADALAJARA, Mexico — Medical, surgical, vascular, and rehabilitation/prevention: these are the four key teams that should be involved in the treatment of patients ...

Off-loading of the affected area is the standard of care and commonly results in healing the noninfected neuropathic ulcer. Methods of off-loading can be broadly categorized as external ...

DiaSafe™ technology for non-invasive DFU risk assessment and early intervention*The DFU treatment market is estimated to be ...

One Acadiana man— was diagnosed with diabetes nearly 40 years ago. He was one of the first to receive a procedure three years into its trial stages—we now know it relieves nearly 90 percent of ...

Severe pain, tingling, or a burning sensation in the feet can be early signs of Diabetic Foot, a serious complication of diabetes. If blisters appear or a wound caused by a minor injury fails to heal ...

BioStem Technologies, Inc. (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for ...

ROCHESTER, Minn.--(BUSINESS WIRE)--RION, a clinical-stage regenerative medicine company at the forefront of exosome-based therapeutics, announced today that it has completed patient enrollment in its ...

Aroa Biosurgery Ltd (($AU:ARX)) announced an update on their ongoing clinical study. Study Overview: Aroa Biosurgery Ltd is conducting a clinical ...